Arcutis Biotherapeutics, Inc. (ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. With its headquarters located in Westlake Village, California, the company operates with a bold vision of applying biopharmaceutical science to dermatology for the betterment of patients’ health and quality of life.
Arcutis uses innovative technologies to accelerate the discovery and development of significant therapies for a variety of skin conditions. The company's unique approach combines an appreciation for the complexities of skin biology with insight into patients' needs. This thoughtful approach, combined with the technical sophistication and robust drug development capabilities, enables Arcutis to rapidly advance novel molecules into the clinic.
The company's portfolio is focused on immunology and inflammation. Central to this portfolio is ARQ-151 (topical roflumilast cream), an investigational nonsteroidal, once-daily, topical PDE4 inhibitor for the potential treatment of chronic skin conditions such as plaque psoriasis and atopic dermatitis. The drug is currently in Phase 3 clinical trials, with the company also planning to investigate its potential use in seborrheic dermatitis and scalp psoriasis.
In addition to ARQ-151, Arcutis is also developing ARQ-154 (topical roflumilast foam), a potential treatment for common skin disorders such as seborrheic dermatitis and scalp psoriasis, and ARQ-252, a selective JAK1 inhibitor, for hand eczema and vitiligo.
Arcutis Biotherapeutics, Inc. successfully launched its Initial Public Offering (IPO) on January 31, 2020, and currently trades under the ticker symbol ARQT on the Nasdaq Global Market. It's led by an experienced management team with a reputation for successfully pushing forward new treatments to the market and achieving high-value outcomes.
The company truly embodies its motto: 'Dermatology, reimagined'. By placing patients at the center of all operations, Arcutis genuinely believes in unlocking new opportunities to improve patients' lives. Moving forward, the company has plans to continue to leverage novel technologies to discover new molecules that will change the landscape of dermatological treatments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) volatility, noting strong near and mid-term sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and an exceptional 58.1:1 risk-reward setup targeting a 16.1% gain. The piece outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to optimize trading decisions.
_07_03_2026_03_50_21_133108.jpg)
Masaru Matsuda, EVP and Chief Legal Officer of Arcutis Biotherapeutics (NASDAQ:ARQT), sold 3,674 shares of the company's common stock on September 16, 2026. The transaction was executed under a Rule 10b5-1 trading plan adopted on June 5, 2026, at a weighted average price of $25.0009 per share. Following the sale, Matsuda beneficially owns 112,508 shares.
Arcutis Biotherapeutics stock jumped 11.19% after CEO Frank Watanabe reiterated confidence in their ZORYVE psoriasis and dermatitis franchise at a Morgan Stanley conference, projecting $2.5 billion to $3 billion in peak sales. The stock's rise, however, occurred on low trading volume, suggesting existing shareholders' conviction rather than new institutional buying. TIKR's model values the stock significantly higher at $102 by 2030, based on anticipated ZORYVE market penetration exceeding analyst expectations.
Masaru Matsuda, EVP and Chief Legal Officer at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 9,989 shares worth approximately $249,985 on September 8, 2026, under a pre-arranged trading plan. This sale occurred as ARQT stock trades at $23.38, down 19% year-to-date but up 32% over the past year. The company recently reported strong Q2 2026 financial results, with net product revenue surging to $129.9 million, exceeding forecasts and leading to profitability and a raised price target from Guggenheim.
Arcutis Biotherapeutics has updated the prescribing information for its ZORYVE medication, available in aerosol and foam formulations. The updated documentation, released on September 4, 2026, details the clinical specifications and usage guidelines for these products in the DailyMed database. This information provides comprehensive data on the administration and chemical composition of the roflumilast-based treatments for healthcare providers.
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) using AI models to provide institutional trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, offering specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis identifies an exceptional short setup with a high risk-reward ratio.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14-16, 2026, in New York. The company will hold a fireside chat on Wednesday, September 16, 2026, at 1:50 p.m. ET, with a webcast available through their website for 180 days. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a portfolio of treatments for chronic inflammatory skin diseases.
Arcutis Biotherapeutics (ARQT) has experienced recent share price fluctuations, with a 12% drop over the last month but a 16% increase over the past three months. While a detailed revenue and earnings forecast suggests the company is undervalued at $36.88 per share compared to its $24.87 close, its current P/E ratio of 109.6x is significantly higher than peers, indicating potential valuation risk. Investors are encouraged to review the underlying numbers and consider risks related to its key product ZORYVE's performance and payer support.
Arcutis Biotherapeutics Board Member Terrie Curran exercised stock options for 1,072 shares of ARQT, valued at $18,642, as revealed in an SEC filing on August 24. The company's stock was up by 0.81% at $24.9 following the transaction. The article also provides an analysis of Arcutis Biotherapeutics' financial performance, highlighting strong revenue growth and gross margin but noting challenges in EPS and debt management.